X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/12/09/2793433/0/en/New-data-reinforce-the-benefit-of-early-preventative-treatment-with-Roche-s-Hemlibra-for-babies-with-severe-haemophilia-A.html
https://www.globenewswire.com/news-release/2023/02/01/2599083/0/en/European-Commission-approves-label-expansion-of-Roche-s-Hemlibra-to-include-people-with-moderate-haemophilia-A-in-the-EU.html
https://www.fiercebiotech.com/biotech/sanofi-dives-deeper-phase-3-data-hemlibra-rival-fda-decision-approaches
https://www.globenewswire.com/news-release/2022/12/16/2575433/0/en/CHMP-recommends-expansion-of-EU-label-for-Hemlibra-to-include-people-with-moderate-haemophilia-A.html
https://www.globenewswire.com/news-release/2022/12/11/2571422/0/en/Interim-data-from-phase-III-study-presented-at-ASH-2022-show-Hemlibra-achieved-meaningful-bleed-control-in-infants-from-birth.html
https://endpts.com/sanofi-nabs-priority-review-for-hemophilia-a-program-as-pharma-awaits-fda-decision/
https://scrip.pharmaintelligence.informa.com/SC146720/Japan-Specific-Approval-For-Hemlibra-In-Acquired-Hemophilia-A
https://www.globenewswire.com/news-release/2022/07/11/2477048/0/en/New-data-from-phase-III-HAVEN-6-study-reinforce-favourable-safety-and-efficacy-profile-of-Roche-s-Hemlibra-in-people-with-moderate-or-mild-haemophilia-A.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761083
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761083
https://www.clinicaltrialsarena.com/news/roche-hemlibra-bleed-haemophilia-trial/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761083
https://www.globenewswire.com/news-release/2021/07/02/2257167/0/en/Roche-to-present-new-data-at-the-ISTH-2021-Congress-highlighting-long-standing-commitment-to-advancing-haemophilia-A-standard-of-care.html
https://www.fiercebiotech.com/biotech/spark-therapeutics-nabs-cmo-from-new-owner-roche
http://www.pmlive.com/pharma_news/new_data_reinforces_safety_profile_of_roches_hemlibra_1344773
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72779a-eng.php
http://www.pmlive.com/pharma_news/novo_nordisk_hits_pause_on_rival_to_hemlibra_for_haemophilia_1329367
https://www.fiercepharma.com/pharma/ocrevus-hemlibra-offset-roche-s-biosim-loss-but-what-about-those-lackluster-xofluza-sales
https://www.biospectrumasia.com/news/25/14789/taiwan-fda-approves-chugais-hemlibra-for-hemophilia-a.html
https://endpts.com/roche-surprise-delays-4-3b-spark-buyout-again-as-regulators-hover/
https://www.fiercebiotech.com/biotech/novo-taps-bluebird-bio-for-gene-editing-tech
https://endpts.com/roche-sets-new-deadline-for-spark-acquisition-as-divestiture-speculations-brew/
https://endpts.com/is-the-ftc-about-to-force-roche-to-divest-a-key-hemophilia-program-before-green-lighting-spark-buyout/
https://www.fiercepharma.com/pharma/roche-s-tecentriq-a-european-hot-streak-bags-two-new-lung-cancer-approvals
https://www.biospace.com/article/roche-spark-push-back-stock-offer-deadline-as-ftc-reviews-continue/?s=79
https://www.fiercepharma.com/pharma/roche-s-hemlibra-set-to-treat-much-larger-group-patients-england
http://www.pharmatimes.com/news/nhs_to_reimburse_hemlibra_1298460
https://www.fiercepharma.com/marketing/roche-shows-off-torrent-hemlibra-data-amid-hemophilia-gene-therapy-deal-delays?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/roche-touts-phase-2-gazyva-data-lupus-nephritis-same-day-as-new-approval
https://www.biospace.com/article/roche-s-acquisition-of-spark-hits-another-regulatory-snag-in-the-u-s-and-u-k-/?s=79
https://www.fiercepharma.com/pharma/roche-snags-fda-approval-for-polivy-combo-certain-dlbcl-patients
https://www.bloombergquint.com/business/roche-s-new-cancer-ms-drugs-pay-off-with-a-forecast-boost
https://www.fiercepharma.com/pharma/roche-s-stellar-hemlibra-ocrevus-results-q1-prompt-sunnier-2019-outlook
http://www.pmlive.com/pharma_news/hemlibra_off_to_a_flyer_as_roche_raises_2019_forecasts_1284759
http://www.pharmafile.com/news/520427/roche-and-chugais-hemlibra-scoops-eu-approval-prevention-severe-haemophilia-without-fact
https://www.statnews.com/2019/02/05/as-pace-of-price-hikes-slow-storm-clouds-are-gathering-over-pharma-companies/
https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-28-31-january-2019_en.pdf
https://www.fiercepharma.com/pharma/icer-lays-out-plans-to-scrutinize-pharma-s-costliest-price-hikes
https://endpts.com/gilead-locks-in-daniel-oday-as-ceo-tapping-the-roche-vet-to-rejuvenate-growth/
https://www.reuters.com/article/us-roche-hemlibra/roche-says-hemlibra-effective-in-pivotal-study-idUSKBN1O22F9
Market Place
Share 
